Orion Pharma's Total Liabilities for the quarter that ended in Mar. 2026 was BDT35,712 Mil.
Orion Pharma's quarterly Total Liabilities
increased
from Sep. 2025 (BDT34,671.48 Mil) to Dec. 2025 (BDT35,394.84 Mil) and
increased
from Dec. 2025 (BDT35,394.84 Mil) to Mar. 2026 (BDT35,712.02 Mil).
Orion Pharma's annual Total Liabilities
declined
from Jun. 2023 (BDT31,720.52 Mil) to Jun. 2024 (BDT31,349.93 Mil) but then
increased
from Jun. 2024 (BDT31,349.93 Mil) to Jun. 2025 (BDT34,178.06 Mil).
Orion Pharma Total Liabilities Related Terms
Orion Pharma Total Liabilities Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Orion Pharma's Total Liabilities for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of BDT35,712 Mil mean?
Orion Pharma (DHA:ORIONPHARM) has a Total Liabilities of BDT35,712 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Orion Pharma and its competitors.
Is Orion Pharma's Total Liabilities too high?
Orion Pharma's current Total Liabilities is BDT35,712 Mil. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Total Liabilities compare to CEG and VST?
Orion Pharma's Total Liabilities of BDT35,712 Mil can be compared against companies in the Utilities - Independent Power Producers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for an Utilities - Independent Power Producers company?
A good Total Liabilities depends on the Utilities - Independent Power Producers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Orion Pharma and its competitors. Orion Pharma's current Total Liabilities is BDT35,712 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.31, compared to a current price of BDT28.60 — trading 40.8% above its estimated fair value. The current Total Liabilities is BDT35,712 Mil. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Total Liabilities is BDT35,712 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.60 is trading 40.8% above its estimated GF Value™ of BDT20.31.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Total Liabilities: BDT35,712 Mil
GF Value™: BDT20.31 vs. price of BDT28.60 (40.8% above fair value)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
